Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data.

Bone Marrow Transplant · 2025 · PMC11726458 · PMID 39500997

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the RCT, compared to busulfan-based reduced intensity conditioning, the treosulfan-fludarabine regimen showed a trend towards better survival outcomes with significantly improved event-free survival at 24 months post-HCT (Supplementary Fig. 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.